Dopamine Agonists - Administration & dosage
Research News and Information

Monday, November 23, 2009

[Management of Parkinson's disease in 2009]

24 Aug 2009 The cause of Parkinson's disease remains unknown and no cure or prevention exists so far. Levodopa remains by far the most potent symptomatic therapy, but induces side-effects such as motor fluctuations and abnormal movements, which can somewhat be ... Read more...

High doses of rotigotine transdermal patch: results of an open-label, dose-escalation trial in patients with advanced-stage, idiopathic Parkinson disease.

29 Jun 2009 OBJECTIVE: The objective of the study was to determine the maximal achievable dose of rotigotine by assessing the tolerability of escalating doses of rotigotine transdermal patch in patients with advanced-stage Parkinson disease. METHODS: ... Read more...

Dopamine agonists for early Parkinson disease.

29 Jun 2009 BACKGROUND: Dopamine agonists are being used increasingly as first-line treatment for Parkinson disease, but uncertainty remains about their clinical- and cost-effectiveness relative to levodopa. OBJECTIVES: This meta-analysis aims to quantify more ... Read more...

Latest indexed articles for 'Dopamine Agonists - Administration & dosage'

These are the very latest articles for this heading:

• Drug-induced compulsive behaviors: exceptions to the rule. 30 Aug 2009
• [Management of Parkinson's disease in 2009] 24 Aug 2009
• Panic attack-like episodes possibly associated with ropinirole. 29 Jun 2009
• High doses of rotigotine transdermal patch: results of an open-label, dose-escalation trial in patients with advanced-stage, idiopathic Parkinson disease. 29 Jun 2009
• Dopamine agonists for early Parkinson disease. 29 Jun 2009
• Impact of serotonin 2C receptor null mutation on physiology and behavior associated with nigrostriatal dopamine pathway function. 22 Jun 2009
• Agonist or levodopa for Parkinson disease? Ultimately, it doesn't matter; neither is good enough. 14 Jun 2009
• Randomized, placebo-controlled, double-blind study of ropinirole in chronic stroke. 9 Jun 2009
• Dose-dependent inverted U-shaped effect of dopamine (D2-like) receptor activation on focal and nonfocal plasticity in humans. 11 May 2009
• Long-term retention rate of pramipexole in the treatment of Parkinson's disease. 3 May 2009
• Low dose apomorphine induces context-specific sensitization of hypolocomotion without conditioning: support for a new state dependent retrieval hypothesis of drug conditioning and sensitization. May 2009
• Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease. 28 Apr 2009
• Dopaminergic activation excites rat lateral habenular neurons in vivo. 13 Apr 2009
• The duration of the motor response to apomorphine boluses is conditioned by the length of a prior infusion in Parkinson's disease. 13 Apr 2009
• Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment. 7 Apr 2009
• Co-administration of the partial dopamine D2 agonist terguride with L-dopa attenuates L-dopa-induced locomotor sensitization in hemiparkinsonian mice. 3 Apr 2009
• [Selection of management tactics in treatment of giant prolactin-secreting pituitary adenomas] 30 Mar 2009
• Low-dose cabergoline causing valvular heart disease in a patient treated for prolactinoma. 30 Mar 2009
• Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy. 30 Mar 2009
• The neurotensin agonist NT69L improves sensorimotor gating deficits in rats induced by a glutamatergic antagonist, but not by dopaminergic agonists. 30 Mar 2009

See a longer list of these articles.

Technical information about 'Dopamine Agonists'

Definition: Drugs that bind to and activate dopamine receptors.

Registry Number: 0

Descriptor UI: D018491

Alternative terms: Dopamine Agonists; Agonists, Dopamine; Receptor Agonists, Dopamine; Dopamine Receptor Agonist; Agonist, Dopamine Receptor; Receptor Agonist, Dopamine; Dopamine Receptor Agonists; Dopaminergic Agonists; Agonists, Dopaminergic; Dopaminergic Agonist; Agonist, Dopaminergic; Agonists, Dopamine Receptor; Dopamine Agonist; Agonist, Dopamine;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications;

Tree Number: D27.505.519.625.150.151; D27.505.696.577.150.151;

Online Note: use DOPAMINERGIC AGENTS to search DOPAMINE AGONISTS & DOPAMINE RECEPTOR AGONISTS 1989-94

History Note: 95; DOPAMINE AGONISTS & DOPAMINE RECEPTOR AGONISTS were see DOPAMINERGIC AGENTS 1989-94

Technical Notes: GEN or unspecified; prefer specifics; DF: DOPAMINE AGON or DOPAMINE AG